Company intelligence / Profile preview

LayerBio

Medford, Massachusetts, United Stateslayerbio.com ↗

Ownership: Private
Employees: ~3
Development stage: Preclinical

Overview

LayerBio’s lead product OcuRing™ delivers drugs via a bioerodible ring placed on intraocular lenses during cataract surgery to prevent complications such as inflammation. The company has received significant non-dilutive funding from the NIH, NSF, and DoD to advance its clinical programs. Lead assets include formulations of corticosteroids and NSAIDs for ophthalmic use. Clinical results are not yet published.

Therapeutic areas: OtherOphthalmology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

OcuRing-K

Unknown

Partnerships

Sponsored research collaborations with industry partnersU.S. Department of Defense grant supportNIH/NSF SBIR grants

Beyond the preview

Go deeper on LayerBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LayerBio.

Explore the full profile